PBS to delist Zoladex 3.6 mg implant from November 2026

PBS to delist Zoladex 3.6 mg implant from November 2026

13 May 2026

The decision follows a request from AstraZeneca Pty Ltd, the medicine’s sponsor, which advised it is withdrawing the product for commercial reasons.

AstraZeneca has also confirmed the medicine will not be supplied on private prescriptions after it is removed from the PBS. The Government says it cannot require companies to continue listing medicines on the PBS, even if there is clinical need.

The Pharmaceutical Benefits Advisory Committee (PBAC) has advised that removing this product may lead to an unmet clinical need for some patients.

Other treatment options will remain available on the PBS, including the 10.8 mg goserelin implant and other GnRH agonists used for prostate cancer and endometriosis.

However, there are currently no direct PBS alternatives for some indications, including hormone receptor positive breast cancer and anticipated premature ovarian failure.

AstraZeneca has indicated it may seek approval to expand the use of its 10.8 mg implant to cover additional indications in the future, subject to regulatory and reimbursement processes.

Patients currently using the 3.6 mg implant are being advised to speak with their treating doctor about alternative treatment options.

https://www.pbs.gov.au/

Source: Australian Government Department of Health, Disability and Ageing (PBS Notice)
 
 

Categories

Popular Posts

Recent Posts

Tags